Literature DB >> 8400280

Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa.

Y Jin1, H C Dietz, A Nurden, P F Bray.   

Abstract

Glanzmann thrombasthenia (GT) is the most common inherited disorder of platelets. Most of the molecular defects previously identified in GT have been caused by point (or other small) mutations in the genes for glycoprotein (GP) IIb or GPIIIa. We have used single-strand conformation polymorphism (SSCP) analysis to rapidly identify single-base changes in the GPIIIa gene. Using genomic DNA from normal individuals and patients with GT, each GPIIIa exon and a short stretch of flanking intronic sequence was amplified, heat-denatured, and separated in nondenaturing acrylamide gels. Only those fragments with an abnormal migration pattern were isolated and the nucleotide sequence determined. Using SSCP, we detected the polymorphism in the HPA-1 (P1A) system and all three known silent polymorphisms in the GPIIIa gene. Screening 14 GPIIIa exons from 5 patients with GT, one mutant allele was identified. The nucleotide sequence of the abnormal 240-bp SSCP fragment was determined and a G-->A substitution in the splice donor site of exon iv was identified. Analysis of platelet RNA resulting from this mutation showed two mRNA species: one contained a deletion of exon iv, whereas the other had a 27-bp addition to exon iv due to the use of a cryptic splice site in the downstream intron. Single-base substitutions are the most common mutation in GT and often result in abnormal mRNA splicing. SSCP is a rapid and sensitive technique for identifying mutations or polymorphisms in the GPIIIa gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8400280

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  A multilocus genotyping assay for candidate markers of cardiovascular disease risk.

Authors:  S Cheng; M A Grow; C Pallaud; W Klitz; H A Erlich; S Visvikis; J J Chen; C R Pullinger; M J Malloy; G Siest; J P Kane
Journal:  Genome Res       Date:  1999-10       Impact factor: 9.043

2.  Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression.

Authors:  E Leygue; L Murphy; F Kuttenn; P Watson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

3.  Rapid and effective processing of blood specimens for diagnostic PCR using filter paper and Chelex-100.

Authors:  J M Polski; S Kimzey; R W Percival; L E Grosso
Journal:  Mol Pathol       Date:  1998-08

4.  Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection.

Authors:  Y Jin; H C Dietz; R A Montgomery; W R Bell; I McIntosh; B Coller; P F Bray
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

5.  Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance? : a study in older patients.

Authors:  Elod Papp; Viktoria Havasi; Judit Bene; Katalin Komlosi; Gabor Talian; Gergely Feher; Beata Horvath; Laszlo Szapary; Kalman Toth; Bela Melegh
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Three novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb, but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi.

Authors:  E J R Nelson; J Li; W B Mitchell; M Chandy; A Srivastava; B S Coller
Journal:  J Thromb Haemost       Date:  2005-12       Impact factor: 5.824

7.  A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia.

Authors:  N Rosenberg; H Hauschner; H Peretz; R Mor-Cohen; M Landau; B Shenkman; G Kenet; B S Coller; A A Awidi; U Seligsohn
Journal:  J Thromb Haemost       Date:  2005-12       Impact factor: 5.824

8.  Intrinsic differences between authentic and cryptic 5' splice sites.

Authors:  Xavier Roca; Ravi Sachidanandam; Adrian R Krainer
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.